NOPR Collection:

Integrative Therapy based on Yoga, Ayurveda and Modern Western Medicine for treatment of high-risk cases of COVID-19: A telemedicine-based case series

2022-07-29T07:31:05Z

Title: Integrative Therapy based on Yoga, Ayurveda and Modern Western Medicine for treatment of high-risk cases of COVID-19: A telemedicine-based case series Authors: Bentur, S A; Mishra, A; Kumar, Y; Thakral, S; Sanjiv; Garg, R Abstract: We report a telemedicine-based case-series of 30 mild/moderate (classification based on guidelines by Ministry of Health and Family Welfare, Government of India) COVID-19 patients, treated using Integrative Therapy based on Ayurveda, Yoga and Modern Western Medicine, i.e., MWM (allopathy). Cases were high-risk owing to comorbidities like Diabetes Mellitus, Hypertension, Coronary Artery Disease, Ulcerative colitis, Chronic Kidney Disease and/or age above 60. The cases have been categorized into YAS (Yoga-Ayurveda based treatment, with possibly allopathic Supplements: 4 patients), YASP (Yoga-Ayurveda based treatment, with possibly allopathic Supplements and Paracetamol: 6 patients), YAM (Yoga-Ayurveda based treatment, and MWM as adjunct: 6 patients), MYA (first tried MWM, later switched to Yoga-Ayurveda: 14 patients). Based on each patient’s symptoms and co-morbidities, a personalized treatment plan including Ayurvedic medicines, Yoga protocol, dietary recommendations and lifestyle modifications was prescribed by a registered Ayurveda doctor and a Yoga consultant. More than half of symptomatic patients started improving within 5 days (90% within 9 days); more than 60% reported at least 90% recovery within 10 days. Six patients with oxygen saturation (SpO2) below 95%, benefited through Makarasana and Shithilasana; none progressed to composite endpoints (consisting of admission to Intensive Care Unit, invasive ventilation or death). Considering that approximately 19.3% of the patients with these comorbidities progress to composite end points, the p-value is 7.21 x 10−3. The Integrative Therapy, incorporating Yoga and Ayurveda with MWM, may offer an economical, scalable treatment option for COVID-19 by reducing burden on healthcare facilities and preventing risk-exposure of healthcare workers. Page(s): 475-488

Antimicrobial and anti-inflammatory response by two formulations of Jatyadi thailam in healing diabetic foot ulcers

2022-07-28T12:32:26Z

Title: Antimicrobial and anti-inflammatory response by two formulations of Jatyadi thailam in healing diabetic foot ulcers Authors: Swathi, K; Sumathi, S; Kumar, Somit; Sripathi, Shubashini K Abstract: Jatyadi thailam is a polyherbal formulation used by Ayurvedic practitioners and clinically reported for the treatment of inflammation related ailment specifically in non-healing chronic foot ulcers. The study is focused to validate and compare the Ayurvedic Formulary of India (AFI) and Yogagrantha (YG) formulations of Jatyadi thailam in vitro, for its antimicrobial and anti-inflammatory potential. Antimicrobial activity of thailam was determined by broth microdilution method for its minimal inhibitory concentration (MIC) and microbicidal activity (MBC/MFC). In vitro anti-inflammatory activity of varying concentrations of Jatyadi thailam were determined by assaying albumin denaturation inhibition, membrane stabilization (hypotonicity-induced hemolysis), heat induced hemolysis and antiproteinase activities. Highest bactericidal and fungicidal activity was recorded by AFI formulation of Jatyadi thailam showing low MIC values compared to YG formulation. Of all the tested bacterial strains, both the formulations showed great bactericidal effect against Staphylococcus aureus. Both the formulations exhibited significant dose dependent anti-denaturation and anti-proteinase activities. The thailam also showed marked stabilization of human red blood cell (HRBC) membrane against thermal hemolysis. Our study confirmed AFI formulation of Jatyadi thailam possessed better antimicrobial and significant (p<0.05) anti-inflammatory effect. AFI Jatyadi thailam was more effective than YG formulation in terms of dose-dependence activity against infection causing microbes and toxic inflammatory mediators. The outcome of the study emphasizes the positive therapeutic potential of Jatyadi thailam to combat infectious and inflammatory conditions. Page(s): 489-498

Ayurvedic herbal extracts suppress Candidal biofilms in vitro

2022-07-28T12:28:54Z

Title: Ayurvedic herbal extracts suppress Candidal biofilms in vitro Authors: Wijesinghe, G K; Jayarathna, T A; Dilhari, K A A; Gunasekara, C; Fernando, N; Kottegoda, N; Samaranayake, L P; Weerasekera, M M Abstract: Plant derivatives have been used for centuries to treat various health disorders of the human including microbial infections. A vast majority of these infections are initiated and perpetuated by biofilms. This study investigated the biofilm suppressant effect of phytomedicinal preparations used widely in traditional Ayurvedic medicine. Triphala, a mixture of Terminalia bellirica, Terminalia chebula and Emblica officinalis and Mimusops elengi bark extract. Inhibitory effect of extracts was first investigated against the planktonic C. albicans and C. tropicalis using well diffusion method. Minimum biofilm inhibitory concentration for in-vitro biofilms was determined by MTT assay. The biofilm suppressant effect was determined by measuring biofilm viability at different time intervals, post-exposure to the two herbal extracts, using MTT. Scanning electron microscopy was performed to assess the post-exposure biofilm architecture. Triphala inhibited both species of the planktonic yeasts and only the biofilm phase of C. tropicalis. Further, biofilm inhibition was seen in the co-cultured mixed species C. albicans and C. tropicalis biofilms with Triphala treatment. Triphala did not have any inhibitory effect on C. albicans. M. elengi had no inhibitory effect on biofilms of either Candida species. Scanning electron microscopy (SEM) revealed increased cell density of C. albicans in the biofilm. However, Triphala treatment had an inhibitory effect against C. tropicalis biofilms. SEM imaging revealed altered cell morphology of C. tropicalis cells in the biofilm after exposure to Triphala. In conclusion Triphala, but not M. elengi, extracts exhibit selective and differential biofilm inhibitory activity against Candida species. C. albicans biofilms are more resistant to the anti-biofilm activity of Triphala. Page(s): 499-504

Fingerprinting of Sahaj Vati, additive for natural lovastatin production

2022-08-17T11:23:31Z

Title: Fingerprinting of Sahaj Vati, additive for natural lovastatin production Authors: Yadav, Kapil Deo Abstract: The lovastatin has been used in hypercholesterolemia and heart diseases for therapeutic as well as preventative purposes and it is naturally obtained from filamentous fungi such as Aspergillus through biotechnological approach. The additives in fungal media which enhances the fungal growth should also increase the production of lovastatin. Finger printing of Sahaj Vati, a herbo-mineral formulation comprising mixture of Plumbago zeylanica, Curcuma longa, Shilajeet, Commiphora mukul and Clerodendrum phlomidis powder to be added in medium for fungal growth. The fungal growth activity of both batches of Sahaj Vati was tested for fungal isolate of A. flavus by contact measure through hyphal development restraint test utilizing Potato dextrose agar (PDA) and SMKY medium followed by chromatographic and different techniques for standardization. Sahaj Vati has lower antifungal index & increased the fungal biomass and separation of compound was higher in mobile phase Benzene: Ethyl acetate: Pyridine: 5:4.9:0.1 & Hexane: Chloroform: Pyridine: 2.7:1. Sahaj Vati increased the growth and biomass of A. flauvs which may be used for natural production of lovastatin. Page(s): 505-510